Enlivex Announces Upcoming Virtual Investor Conference Participations
Enlivex Therapeutics (Nasdaq: ENLV), a clinical-stage immunotherapy company, announced its participation in two upcoming investor conferences. Management will join the 2nd Annual European Healthtech CEO Forum on March 9, focusing on patient care during the pandemic. They will also present at the H.C. Wainwright Global Life Sciences Conference on March 10, addressing innovative allogeneic cell-based immunotherapy in oncology. Enlivex is developing Allocetra™, a cell therapy aimed at reprogramming macrophages to their homeostatic state, potentially aiding in severe diseases like COVID-19 and solid cancers.
- None.
- None.
Nes Ziona, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the following investor conferences:
- 2nd Annual European Healthtech CEO Forum for Partnering and Investments (https://www.sachsforum.com/2ehtf-about.html)
- Panel participation (March 9th, 16:20 CET): Patient Care in the Time of the Pandemic Panel
- H.C. Wainwright Global Life Sciences Conference 2021
- Corporate presentation will be available on the conference website (https://hcwevents.com/globalconference/) starting March 9 at 7:00 EST
- Panel participation (March 10th, 12:00 EST): Novel Approaches for Allogeneic Cell-Based Immunotherapy: Disruptive Applications in Oncology and Beyond
ABOUT ALLOCETRATM
AllocetraTM is a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as “unmet medical needs”, as a stand-alone therapy or in combination with leading therapeutic agents.
ABOUT ENLIVEX
Enlivex is a clinical stage immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com
INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com
FAQ
What events is Enlivex Therapeutics participating in March 2021?
When will Enlivex present its corporate information at the H.C. Wainwright conference?
What is Allocetra™ developed by Enlivex?
What is the significance of macrophage reprogramming in Enlivex's therapy?
How does Allocetra™ relate to unmet medical needs?
